Released Nov 8, 2023, after the close
10-Q filed Nov 8, 2023, 39 days after period end · 0000950170-23-061134
Q3 2023 · 10-Q
Revenue$0.00$0.00 no prior Q3 2022 on fileno prior Q2 2023 on file
Net Income-$14.42M-$14.42M N/M vs Q3 2022N/M vs Q2 2023
EPS Diluted-$3.29-$3.29 N/M vs Q3 2022N/M vs Q2 2023
Operating Income-$15,048,000N/M
Operating Cash Flowderived-$13,848,000N/M
Free Cash Flowderived-$13,984,000N/M
What the release said
The release
Same quarter
| Metric | Q3 2023 | Q3 2022 | Q3 2021 | Q3 2020 |
|---|---|---|---|---|
| Revenue | $0.00 | — | $6.25M | $34.61M |
| Net Income | -$14.42M | -$23.15M | -$18.80M | -$3.35M |
| EPS Diluted | -$3.29 | -$0.48 | -$0.41 | -$0.09 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR